Browse by author
Lookup NU author(s): Professor Azfar ZamanORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© The Author(s) 2023.Transcatheter aortic valve implantation (TAVI) is an effective and established treatment for symptomatic aortic stenosis. However, there is a lack of consensus concerning the need for peri- and post-procedural anti-thrombotic medication. Contemporary guidelines recommend that anti-thrombotic therapy is balanced against a patient’s bleeding risk following TAVI, but do not fully consider the evolving evidence base. The purpose of the Delphi panel recommendations presented here is to provide a consensus elicited from a panel of experts who regularly prescribe anti-thrombotic therapy post-TAVI. The goal was to address evidence gaps across four key topics: anti-thrombotic therapy (anti-platelet and/or anti-coagulant) in TAVI patients in sinus rhythm; anti-thrombotic therapy in TAVI patients with AF; direct oral anti-coagulants versus vitamin K antagonists; and the need for UK/Ireland specific guidance. This consensus statement aims to inform clinical decision-making by providing a concise, evidence-based summary of best practice for prescribing anti-thrombotic therapies following TAVI and highlights areas where further research is needed.
Author(s): Zaman A, Prendergast B, Hildick-Smith D, Blackman D, Anderson R, Spence MS, Mylotte D, Smith D, Wilding B, Chapman C, Atkins K, Pollock KG, Qureshi AC, Banning A
Publication type: Article
Publication status: Published
Journal: Interventional Cardiology: Reviews, Research, Resources
Year: 2023
Volume: 18
Online publication date: 10/04/2023
Acceptance date: 11/10/2022
Date deposited: 07/06/2023
ISSN (print): 1756-1477
ISSN (electronic): 1756-1485
Publisher: Radcliffe Medical Media
URL: https://doi.org/10.15420/ICR.2022.11
DOI: 10.15420/ICR.2022.11
Altmetrics provided by Altmetric
